Home › Dystonia › NCT06554288

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Pharmacogenomic Contribution to the Biotransformation of Trihexyphenidyl and Development of a Precision Dosing Model for Children With Dystonia and Cerebral Palsy

Who can join

Ages 5 to 17 · All sexes

Inclusion Criteria:

* Ages 5-17 years of age
* Diagnosis of cerebral palsy and dystonia causing interference
* Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
* Parent/legal guardian is willing and able to provide informed permission/assent for the study

Exclusion Criteria:

* Previously or currently taking trihexyphenidyl
* Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
* A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements

About the study

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

What is being tested

• Trihexyphenidyl (drug)

Sponsor: Children's Mercy Hospital Kansas City · Participants: 40 · Started: Oct 15, 2024

Contact the study team

• Rose Gelineau-Morel, MD · Phone: 816-302-3331
• Rachel Nass · Phone: 8166011354

Official record on ClinicalTrials.gov — NCT06554288

Locations in the U.S.

Conditions

• Dystonia
• Cerebral Palsy

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.